Class I Recall of Percutaneous Thrombolytic Device Class I Recall of Percutaneous Thrombolytic Device
Arrow-Trerotola over-the-wire 7FR PTD kits are being recalled because the orange inner lumen of the catheter's tip may separate from the basket causing injury.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 6, 2021 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Acute heart failure due to aluminum phosphide poisoning - Petrovic M, Otero D, Leigh A, Singh V.
We present a case of severe reversible cardiomyopathy and left ventricular apical thrombus in a patient who worked as an exterminator and had ALP poisoning. ... (Source: SafetyLit)
Source: SafetyLit - November 29, 2021 Category: International Medicine & Public Health Tags: Poisoning Source Type: news

Recurrent VTE More Common Than Thought With Isolated Subsegmental Pulmonary Embolism Recurrent VTE More Common Than Thought With Isolated Subsegmental Pulmonary Embolism
Low-risk patients with isolated subsegmental pulmonary embolism have a higher-than-expected rate of recurrent venous thromboembolism, a new study suggests.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 23, 2021 Category: Intensive Care Tags: Internal Medicine News Source Type: news

HEP-COVID Clinical Trial Results on the Prevention of Blood Clots HEP-COVID Clinical Trial Results on the Prevention of Blood Clots
WebMD's Chief Medical Officer, John Whyte, MD, speaks with Alex Spyropoulos, MD, a thrombosis expert, on his recent HEP-COVID randomized clinical trial involving COVID-19 patients, the blood thinner heparin, and reducing the risk of major blood clots.WebMD (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 17, 2021 Category: Infectious Diseases Tags: Infectious Diseases Expert Interview Source Type: news

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The tria...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Deep vein thrombosis symptoms: Six early stage signs in your leg
DEEP VEIN THROMBOSIS is a blood clot in a vein that can be deadly, and it impacts as many as one in every 1,000 Brits every single year. Here are the six early-stage signs in your leg. (Source: Daily Express - Health)
Source: Daily Express - Health - November 15, 2021 Category: Consumer Health News Source Type: news

Newspath March 2014 - Hypercoagulablity Workup: Antithrombin Deficiency
Hypercoagulability is the main pathologic function needed to form a venous thrombosis (VT), a common cause of morbidity and mortality in many clinical settings. (Source: NewsPath - Pathology News for the Medical Community)
Source: NewsPath - Pathology News for the Medical Community - November 11, 2021 Category: Pathology Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Guideline: Managing Coagulation Disorders in Cirrhosis Guideline: Managing Coagulation Disorders in Cirrhosis
A clinical update from the American Gastroenterological Association focuses on bleeding and thrombosis-related questions in patients with cirrhosis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 5, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

VTE Can Occur in Moderate COVID-19 VTE Can Occur in Moderate COVID-19
A European study has found an elevated risk of venous thromboembolism in COVID-19 patients who were not critically ill.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 2, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Blood clot: Three signs in your leg of deep vein thrombosis - ‘contact your doctor’
BLOOD clots form to try and repair damage to a blood vessel. They are important to spot, as blood clots can cause deep vein thrombosis . This can be dangerous and you will need quick medical attention. (Source: Daily Express - Health)
Source: Daily Express - Health - October 31, 2021 Category: Consumer Health News Source Type: news

Antithrombotic Therapy Not Warranted in COVID-19 Outpatients Antithrombotic Therapy Not Warranted in COVID-19 Outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI, stroke, or hospitalization in the ACTIV-4B trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 20, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Therapeutic - Dose LMWH Cuts Thromboembolism, Deaths in COVID - 19
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high - risk patients in non - ICU, but not ICU, settings (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 15, 2021 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Nursing, Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Half-Dose DOACs Cut Bleeding, Thrombus Risk Post-Watchman Implant Half-Dose DOACs Cut Bleeding, Thrombus Risk Post-Watchman Implant
The risks dropped off sharply after standard postprocedure antithrombotics were replaced by a half-dose DOAC given indefinitely without long-term antiplatelets in an observational study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 15, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

World Thrombosis Day raises worldwide awareness of an urgent and growing health problem – blood clots
World Thrombosis Day (WTD) is a year-long campaign that focuses attention on the underappreciated condition of thrombosis, or blood clots. Unfortunately, one in four people worldwide die each year from conditions caused by thrombosis. Currently, the World Health Assembly has a global target in place to reduce premature deaths from non-communicable disease by 25 percent by 2025 and 30 percent by 2030. Unless thrombosis is addressed on a global scale, achieving this goal will be impossible. “Despite… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 13, 2021 Category: Biotechnology Authors: International Society on Thrombosis and Hemostasis (ISTH) Source Type: news

Hypercoagulability and Thrombosis in COVID-19 Hypercoagulability and Thrombosis in COVID-19
A new study provides valuable insights into the manifestations of pulmonary embolism in patients with COVID-19, and may help clarify the routine use of anticoagulant strategies in COVID-19 patients.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

EU Finds J & J COVID Shot Possibly Linked to Another Rare Clotting Condition EU Finds J & J COVID Shot Possibly Linked to Another Rare Clotting Condition
The European Union's drug regulator on Friday identified a possible link between rare cases of venous thromboembolism with Johnson& Johnson's COVID-19 vaccine and recommended the condition be listed as a side effect of the shot.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 4, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

CVST After COVID-19 Vaccine: New Data Confirm High Mortality Rate CVST After COVID-19 Vaccine: New Data Confirm High Mortality Rate
A new series of cases of cerebral venous sinus thrombosis (CVST) linked to the adenoviral vector COVID-19 vaccines has been reported, confirming the severity of the reaction and the associated high mortality.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 30, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Delayed-onset portal venous thrombosis after ingestion of 3% hydrogen peroxide - Schneir A, Minns AB, Otter J.
BACKGROUND: Identification of portal venous gas on radiographic imaging is well documented after the ingestion of hydrogen peroxide, as is its resolution after hyperbaric therapy. Although hyperbaric therapy may resolve the gastrointestinal symptoms associ... (Source: SafetyLit)
Source: SafetyLit - September 16, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Decompressive Surgery Saves Lives in Severe Cerebral Vein Thrombosis Decompressive Surgery Saves Lives in Severe Cerebral Vein Thrombosis
For patients with large hemorrhagic brain lesions caused by CVT, who are at a very high risk for death, decompressive surgery was associated with remarkably good outcomes in the DECOMPRESS2 study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 15, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Blood clot symptoms: The marking on your leg that could signal deep vein thrombosis
DEEP vein thrombosis occurs when a blood clot forms in a deep vein, usually in a person's leg. A pulmonary embolism happens when the blood clot breaks off and travels from the leg up to the lungs. This means it is important to be aware of the signs on your leg. (Source: Daily Express - Health)
Source: Daily Express - Health - September 15, 2021 Category: Consumer Health News Source Type: news

Study Describes Bleeding Risk With Anticoagulants for VTE Study Describes Bleeding Risk With Anticoagulants for VTE
New research may help doctors assess the long-term risk for major bleeding if anticoagulation for unprovoked venous thromboembolism (VTE) is continued beyond 3 –6 months.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - September 14, 2021 Category: Primary Care Tags: Internal Medicine News Source Type: news

Guidance from the Expert Haematology Panel (EHP) on Covid-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT), British Society for Haematology
Updated Guidance on Management. Version 2.2 31 August 2021 (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 13, 2021 Category: Consumer Health News Source Type: news

Comparison of three interventional approaches to prevent ventilator-associated pneumonia in intensive care units (ICUs): A clinical trial study
Background: Ventilator-associated pneumonia (VAP) is an infectious pulmonary disease that develops after 48 hours of ventilation. To date, several methods have been proposed to reduce VAP occurrence, such as the VAP prevention bundle, which involves raising the head of the bed, reducing sedation, avoiding deep vein thrombosis, and preventing peptic ulcer in the gastrointestinal system. The purpose of this study was to evaluate the role of personnel in hand washing, case airway suctioning, and systematic monitoring in the prevention of VAP.; Methods: In the current clinical trial, 129 patients hospitalized and intubated at ...
Source: Current Awareness Service for Health (CASH) - September 9, 2021 Category: Consumer Health News Source Type: news

COVID-19 Vaccine Janssen and venous thromboembolism, EMA
As part of ongoing safety monitoring of COVID-19 vaccines, PRAC will assess additional data from 2 large trials, which are to be submitted shortly by the marketing authorisation holder, to further evaluate if cases of venous thromboembolism are linked to COVID-19 Vaccine Janssen. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 6, 2021 Category: Consumer Health News Source Type: news

Cerebral Thrombosis After COVID Vax Deadlier Than Sporadic Form Cerebral Thrombosis After COVID Vax Deadlier Than Sporadic Form
The most detailed information reported to date on the cerebral venous thrombosis associated with some COVID-19 vaccines provides updated guidance on how to identify and treat the condition.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 3, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news

Recent COVID-19 infection puts surgical patients at higher blood clot risk, NIHR
Surgical patients who have recently had COVID-19 are more likely to develop potentially fatal post-operative blood clots, a new NIHR-funded study reveals. Researchers discovered that patients diagnosed with current or previous SARS-CoV-2 are more likely to develop postoperative venous thromboembolism (VTE) than those with no history of COVID infection. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 3, 2021 Category: Consumer Health News Source Type: news

What are Some of the Complications of Short Bowel Syndrome?
Discussion Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies in neonates. Mortality rates are from 0-45% depending on infant weight and gestation with more premature and smaller infants having greater mortality. NEC usually occurs in premature infants but it also occurs in term infants. The etiology is unknown but is probably multifactorial with ischemia and/or reperfusion playing some role. There are ‘outbreaks’ of NEC but no causative organism has been identified. Regardless of the originating cause, inflammation of the intestine and release of inflammatory mediators cause...
Source: PediatricEducation.org - August 30, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Covid raises odds for blood clots by 90 percent following surgery - study issues warning
VENOUS thromboembolism has attracted considerable scrutiny in the past year, notably due to its connection with the AstraZeneca vaccine. Now, a study has found that those who undergo surgery after contracting the virus, may be twice as likely to suffer the life-threatening condition. (Source: Daily Express - Health)
Source: Daily Express - Health - August 25, 2021 Category: Consumer Health News Source Type: news

Recent COVID-19 Raises Odds for Clots After Surgery by 90%
WEDNESDAY, Aug. 25, 2021 -- COVID-19 infection significantly increases the risk of dangerous blood clots after surgery, a new study finds. Venous thromboembolism (VTE) is a potential complication of surgery in which blood clots form in the veins.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 25, 2021 Category: General Medicine Source Type: news

NICE venous thromboembolism quality standard update
NICE ’s updated quality standard on venous thromboembolism (VTE) brings together and updates the two existing VTE quality standards. (Source: NHS Networks)
Source: NHS Networks - August 25, 2021 Category: UK Health Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) e...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Venous thromboembolism in adults- quality standard [QS201], NICE (published 19th August 2021)
This updates and replaces quality standards on venous thromboembolism in adults: reducing the risk in hospital (published June 2010), and venous thromboembolism in adults: diagnosis and management (published March 2013). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 20, 2021 Category: Consumer Health News Source Type: news

Bioprosthetic Valve Thrombosis: A Perhaps Not So Rare Complication Bioprosthetic Valve Thrombosis: A Perhaps Not So Rare Complication
Dr Christopher DeSimone speaks with expert Dr Sorin Pislaru on how thrombosis contributes to valve failures and reoperations, and what can be done to avoid it.Mayo Clinic (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 17, 2021 Category: Radiology Tags: Cardiology Commentary Source Type: news

Features of Vaccine-Induced Thrombotic Syndrome Studied
THURSDAY, Aug. 12, 2021 -- Mortality seen in association with vaccine-induced immune thrombocytopenia and thrombosis (VITT) after the first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca) is increased for those with cerebral venous sinus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2021 Category: Pharmaceuticals Source Type: news

Coronavirus disease 2019 (COVID-19) Updates, BMJ Best Practice
1. NICE publishes new guidance on vaccine-induced immune thrombocytopenia and thrombosis. 2. FDA authorises casirivimab/imdevimab for prevention of COVID-19. 3. EMA warns of Guillain-Barre syndrome with Janssen COVID-19 vaccine. 4. EMA authorises use of Moderna COVID-19 vaccine in young people aged 12 to 17 years. 5. CDC warns that vaccinated people with breakthrough infections can spread the Delta variant. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news

Large PICC Size May Up Risk for Thrombosis in Cancer Patients
MONDAY, Aug. 9, 2021 -- Cancer patients receiving chemotherapy intravenously have more than double the risk for developing a blood clot if the catheter occupies more than 45 percent of the vein, according to a study recently published online in BMJ... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 9, 2021 Category: Pharmaceuticals Source Type: news

Pfizer vaccine: Rates of deep vein thrombosis and thrombocytopenia after vaccine increase
AS MANY as 32 million people across the UK will be offered the COVID-19 vaccine in a bid to boost immunity ahead of winter. Although the Pfizer vaccine has proven highly effective at preventing serious illness from COVID-19, a recent study has suggested the jab could carry the rare risk of thrombocytopenia and deep vein thrombosis . (Source: Daily Express - Health)
Source: Daily Express - Health - August 7, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson ’s COVID-19 Shot Works Well Against Delta Variant, Study Finds
Johnson & Johnson’s COVID-19 vaccine helps prevent severe disease among those infected with the Delta variant, according to a trial involving almost 480,000 health workers in South Africa. The study, known as Sisonke, provides the first large-scale evidence that the J&J vaccine works against this dominant variant, according to trial co-lead Glenda Gray. It’s probably more protective against Delta than it was with the earlier beta strain, she said in a presentation Friday. The single-dose shot was 71% effective against hospitalization and as much as 96% effective against death, she said. It also demonstr...
Source: TIME: Health - August 6, 2021 Category: Consumer Health News Authors: Janice Kew and Antony Sguazzin / Bloomberg Tags: Uncategorized COVID-19 Source Type: news

Pharmacomechanical Thrombolysis for Acute DVT Tied to Kidney Injury
Bilateral deep vein thrombosis, single - session treatment, and female sex tied to greater risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 5, 2021 Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Internal Medicine, Emergency Medicine, Nephrology, Oncology, Pharmacy, Surgery, Journal, Source Type: news

Pharmacomechanical Thrombolysis for Acute DVT Tied to Kidney Injury
THURSDAY, Aug. 5, 2021 -- Use of pharmacomechanical thrombolysis (PMT) for treatment of acute deep vein thrombosis (DVT) is associated with a risk for acute kidney injury (AKI) that can progress to chronic renal failure in some patients, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 5, 2021 Category: Pharmaceuticals Source Type: news

Behcet's Syndrome Presenting With Pulmonary Artery Thrombosis Behcet's Syndrome Presenting With Pulmonary Artery Thrombosis
This case demonstrates how early detection of vascular involvement can have a major impact on the prognosis of patients with Behcet's syndrome.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

NICE guideline - blood clotting condition associated with COVID-19 vaccination
NICE has published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations. (Source: NHS Networks)
Source: NHS Networks - August 2, 2021 Category: UK Health Source Type: news

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) [NG200], NICE (published 29th July 2021)
This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome. (Source: Current Awaren...
Source: Current Awareness Service for Health (CASH) - July 29, 2021 Category: Consumer Health News Source Type: news

Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population and in people with COVID-19. (Source: World Pharma News)
Source: World Pharma News - July 28, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Rare blood clot cases not higher after AstraZeneca second dose: Study
The data found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine, Vaxzevria, was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, AstraZeneca said. (Source: The Economic Times)
Source: The Economic Times - July 28, 2021 Category: Consumer Health News Source Type: news